@article{ATM23669,
author = {Laura Bender and Guillaume Meyer and Elisabeth Quoix and Bertrand Mennecier},
title = {Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report},
journal = {Annals of Translational Medicine},
volume = {7},
number = {5},
year = {2019},
keywords = {},
abstract = {Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23669}
}